Abstract
Purpose :
The aim of this study was to analyze the expression of immune checkpoint inhibitors in uveal melanoma and its prognostic significance<embed height="0" id="xunlei_com_thunder_helper_plugin_d462f475-c18e-46be-bd10-327458d045bd" type="application/thunder_download_plugin" width="0" />
Methods :
23 enucleated eyes from UM patients with clinical information were analyzed. Immunostaining was performed with antibodies including: PDL1, CTLA4, IDO1 and TIM3. Retina, breast cancer and tonsil were used as positive control. Immunostaining results were evaluated by 2 pathologists. Univariate analysis was used to evaluate the checkpoint inhibitors association with metastasis free survival (MFS).<embed height="0" id="xunlei_com_thunder_helper_plugin_d462f475-c18e-46be-bd10-327458d045bd" type="application/thunder_download_plugin" width="0" />
Results :
PDL-1 was positive in 54.2% of the cases. PD-L1 expression was associated with a longer MFS (p<0.05). Both IDO1 and TIM3 were expressed in all cases and the most of positive cells were located at the peripheral of tumor lesions. However, we didn’t detect any CTLA4 expression in uveal melanoma.<embed height="0" id="xunlei_com_thunder_helper_plugin_d462f475-c18e-46be-bd10-327458d045bd" type="application/thunder_download_plugin" width="0" />
Conclusions :
PDL-1, IDO1, TIM3, but not CTLA4 were expressed in UM. The expression of PDL-1 in UM is associated with longer MFS. IDO1 and TIM3 were constantly expressed in UM<embed height="0" id="xunlei_com_thunder_helper_plugin_d462f475-c18e-46be-bd10-327458d045bd" type="application/thunder_download_plugin" width="0" />
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.